Q2 EPS Forecast for Esperion Therapeutics Lifted by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for Esperion Therapeutics in a report issued on Wednesday, June 4th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter, up from their prior forecast of ($0.07). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q3 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.20) EPS and FY2027 earnings at $0.09 EPS.

A number of other research firms also recently weighed in on ESPR. The Goldman Sachs Group decreased their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, April 25th. Needham & Company LLC lowered their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JMP Securities restated a "market outperform" rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $6.25.

Esperion Therapeutics Trading Up 3.6%

Shares of Esperion Therapeutics stock opened at $1.16 on Friday. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94. The company's fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.71. The company has a market cap of $229.91 million, a price-to-earnings ratio of -1.81 and a beta of 0.75.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $54.97 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ESPR. Nuveen LLC bought a new position in Esperion Therapeutics in the 1st quarter valued at about $4,446,000. Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after acquiring an additional 1,136,245 shares during the period. Nuveen Asset Management LLC grew its position in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.